title: Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes.
abstract: Proliferation and apoptosis pathways are tightly regulated in a cell by the ubiquitin-proteasome system (UPS) and alterations in the UPS may result in cellular transformation or other pathological conditions. Indeed, the proteasome is often found to be overactive in cancer cells. It has also been found that cancer cells are more sensitive to proteasome inhibition than normal cells, and therefore proteasome inhibitors are pursued as antitumor drugs. The use of the proteasome inhibitor Bortezomib for treatment of multiple myeloma and mantle cell lymphoma has proved this principle. Recent studies have suggested that copper complexes can inhibit proteasome activity and induce apoptosis in some human cancer cells. However, the involved molecular mechanism is unknown. In this study, we investigated the biological activities of four amino acid Schiff base-copper(II) complexes by using human breast (MDA-MB-231 and MCF-7) and prostate (PC-3) cancer cells. The complexes C1 and C3, but not their counterparts C2 and C4, inhibit the chymotrypsin-like activity of purified 20S proteasome and human cancer cellular 26S proteasome, cause accumulation of proteasome target proteins Bax and IκB-α, and induce growth inhibition and apoptosis in concentration- and time-dependent manners. Docking analysis shows that C1, but not C2 has hydrophobic, pi-pi, pi-cation and hydrogen bond interactions with the proteasomal chymotrypsin-like pocket and could stably fit into the S3 region, leading to specific inhibition. Our study has identified the mechanism of action of these copper complexes on inhibiting tumor cell proteasome and suggested their great potential as novel anticancer agents.
authors.affiliation: College of Chemistry and Chemical Engineering, Ocean University of China, Qingdao, Shandong 266100, People's Republic of China.
authors.forename: Jian
authors.initials: J
authors.lastname: Zuo
authors.forename: Caifeng
authors.initials: C
authors.lastname: Bi
authors.forename: Yuhua
authors.initials: Y
authors.lastname: Fan
authors.forename: Daniela
authors.initials: D
authors.lastname: Buac
authors.forename: Chiara
authors.initials: C
authors.lastname: Nardon
authors.forename: Kenyon G
authors.initials: KG
authors.lastname: Daniel
authors.forename: Q Ping
authors.initials: QP
authors.lastname: Dou
mesh_terms: D000596:Amino Acids / Q000737:chemistry / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D020134:Catalytic Domain; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D056831:Coordination Complexes / Q000737:chemistry / Q000494:pharmacology*; D018360:Crystallography, X-Ray; D006801:Humans; D008968:Molecular Conformation; D062105:Molecular Docking Simulation; D046988:Proteasome Endopeptidase Complex / Q000737:chemistry; D061988:Proteasome Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D011485:Protein Binding; D012545:Schiff Bases / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013499:Surface Properties
chemical_list: D000596:Amino Acids; D000970:Antineoplastic Agents; D056831:Coordination Complexes; D061988:Proteasome Inhibitors; D012545:Schiff Bases; D046988:Proteasome Endopeptidase Complex